An Expert View from Dr Elena Wolff-Holz, global head of clinical development at Biocon Biologics, the biosimilar subsidiary ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...

Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

Organon and Shanghai Henlius Biotech have announced that the European Medicines Agency (EMA) has validated a marketing ...

Biosimilar adoption and market dynamics are reshaping managed care, with the Inflation Reduction Act impacting innovation and market incentives. Specialty pharmaceuticals, particularly GLP-1 drugs ...

According to the report, high reliance on out-of-pocket expenditures and limited insurance places an immense financial strain ...

Biosimilars offer affordable medical treatments, but regulatory guidelines need updating to ensure safety, efficacy, and ...